DOCSLIB.ORG

Contents Editorial Commentaries Cerebrovascular Disease Multiple

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Contents Editorial Commentaries Cerebrovascular Disease Multiple May 2019 Volume 90 Issue 5 90 Impact 5 Factor 7.144 Volume 90 Issue 5 Volume Contents Volume 90 Issue 5 | JNNP May 2019 Pages 495–624 Pages JOURNAL OF NEUROLOGY NEUROSURGERY & PSYCHIATRY NEUROSURGERY OF NEUROLOGY JOURNAL Editorial commentaries Neurogenetics J Neurol Neurosurg Psychiatry: first published as on 1 May 2019. Downloaded from ISSUE HIGHLIGHTS 495 Food of the gods for the treatment of multiple 529 Taurine supplementation for prevention of Stroke – Go to rehab Amyotrophic Lateral Sclerosis – It’s evolution Functional Neurological Disease – A sclerosis related fatigue? stroke-like episodes in MELAS: a multicentre, reconciliation Multiple Sclerosis – Cocoa for fatigue Memory – Lost & found P Ragonese Leukodystrophy – A practical approach open-label, 52-week phase III trial May 2019 May Y Ohsawa, H Hagiwara, S Nishimatsu, jnnp.bmj.com 496 Another brick in the wall: further evidence A Hirakawa, N Kamimura, H Ohtsubo, Y Fukai, T Murakami, Y Koga, Y Goto, S Ohta, Y Sunada, Cover image: Brain tree. supporting the role of haematopoietic stem cell on behalf of the KN01 Study Group Editor transplantation in treating multiple sclerosis Matthew C Kiernan (Australia) H L Atkins Deputy Editors 537 Burden of rare variants in causative genes for Karen L Furie (USA) amyotrophic lateral sclerosis (ALS) accelerates Satoshi Kuwabara (Japan) 497 Intense rehabilitation therapy produces very Lawrence Wong (China) large gains in chronic stroke age at onset of ALS Associate Editors S C Cramer H Naruse, H Ishiura, J Mitsui, Y Takahashi, Alan Carson (UK) T Matsukawa, M Tanaka, K Doi, J Yoshimura, Nick Ward (UK) S Morishita, J Goto, T Toda, S Tsuji Peter Warnke (USA) Commissioning Editor Cerebrovascular disease 543 Practical approach to the diagnosis of Martin Turner (UK) 498 Intensive upper limb neurorehabilitation in Web Editors adult-onset leukodystrophies: an updated Clare Caldwell chronic stroke: outcomes from the Queen guide in the genomic era Arun Krishnan Square programme D S Lynch, C Wade, A R B de Paiva, N John, Cindy Lin N S Ward, F Brander, K Kelly Steve Vucic J A Kinsella, Á Merwick, R M Ahmed, J D Warren, Podcast Editor C J Mummery, J M Schott, N C Fox, H Houlden, Elizabeth Highton-Williamson M E Adams, I Davagnanam, E Murphy, JNNP Blog Editors Multiple sclerosis J Chataway Jose Manuel Matamala 507 A randomised double-blind placebo-controlled Thanuja Dharmadasa JNNP Facebook Editors feasibility trial of flavonoid-rich cocoa for Cindy Lin fatigue in people with relapsing and remitting Movement disorders William Huynh multiple sclerosis 555 Association of autonomic symptoms with Editors, Practical Neurology S Coe, J Cossington, J Collett, A Soundy, H Izadi, disease progression and survival in progressive Geraint Fuller (UK) Phil Smith (UK) M Ovington, L Durkin, M Kirsten, M Clegg, supranuclear palsy A Cavey, D T Wade, J Palace, G C DeLuca, Editorial Office M C B Oliveira, H Ling, A J Lees, J L Holton, http://jnnp.bmj.com/ Journal of Neurology Neurosurgery & K Chapman, J-M Harrison, E Buckingham, E De Pablo-Fernandez, T T Warner Psychiatry H Dawes BMJ Publishing Group Ltd BMA House Tavistock Square 514 Prospective phase II clinical trial of autologous London WC1H 9JR, UK haematopoietic stem cell transplant for E: [email protected] treatment refractory multiple sclerosis Twitter: @JNNP_BMJ J J Moore, J C Massey, C D Ford, M L Khoo, MORE CONTENTS ISSN: 0022-3050 (print) ► on September 30, 2021 by guest. Protected copyright. ISSN: 1468-330X (online) J J Zaunders, K Hendrawan, Y Barnett, Impact factor: 7.144 M H Barnett, K A Kyle, R Zivadinov, K C Ma, S T Milliken, I J Sutton, D D F Ma Disclaimer: JNNP is published by BMJ Publishing This article has been chosen by the Editor to be of special interest Group Ltd, a wholly owned subsidiary of the British or importance and is freely available online. Medical Association. The BMJ Group grants editorial freedom to the Editor of JNNP. JNNP follows 522 How common is truly benign MS in a UK guidelines on editorial independence produced by This article has been chosen in conjunction with the BMJ Patient the World Association of Medical Editors and the population? Forum to be of particular interest to patients and is freely available code on good publication practice of the Committee online. on Publication Ethics. E C Tallantyre, P C Major, M J Atherton, JNNP is intended for medical professionals and is W A Davies, F Joseph, V Tomassini, T P Pickersgill, This article has been made freely available online under the provided without warranty, express or implied. Statements in the journal are the responsibility of K E Harding, M D Willis, M Winter, N P Robertson BMJ Journals open access scheme. their authors and advertisers and not authors’ See http://authors.bmj.com/open-access/ institutions, the BMJ Publishing Group or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply The article is part of the Impact Commentaries series endorsement. To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of JNNP or any COPE information in it whether based on contract, tort or otherwise. Readers are advised to verify any information they choose to rely on. Member since 2008 JM00017JM00010 Copyright: © 2019 BMJ Publishing Group. All This journal is a member of and subscribes to the principles of the rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or Committee on Publication Ethics transmitted in any form or by any means, electronic, http://publicationethics.org/ mechanical, photocopying, recording, or otherwise without prior permission. JNNP is published by BMJ Publishing Group Ltd, typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper from sustainable forests. Journal of Neurology Neurosurgery & Psychiatry (ISSN No: 0022-3050) is published monthly by BMJ Publishing Group and is distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431 POSTMASTER: send address changes to The online version of this article contains multiple choice Journal of Neurology Neurosurgery & Psychiatry, questions hosted on BMJ Learning. Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA Contents Volume 90 Issue 5 | JNNP May 2019 Neurodegeneration Cognitive neurology 562 Apraxia screening predicts Alzheimer 586 Story of the ALS-FTD continuum retold: rather J Neurol Neurosurg Psychiatry: first published as on 1 May 2019. Downloaded from pathology in frontotemporal dementia two distinct entities M Pawlowski, V Joksch, H Wiendl, S G Meuth, D E Lulé, H E A Aho-Özhan, C Vázquez, T Duning, A Johnen U Weiland, J H Weishaupt, M Otto, S Anderl-Straub, E Semler, I Uttner, A C Ludolph 590 Inflammatory markers in Alzheimer’s disease Occasional essay and mild cognitive impairment: a meta-analysis 570 Human cerebral evolution and the clinical and systematic review of 170 studies syndrome of amyotrophic lateral sclerosis X-N Shen, L-D Niu, Y-J Wang, X-P Cao, Q Liu, R D Henderson, F C Garton, M C Kiernan, L Tan, C Zhang, J-T Yu M R Turner, A Eisen Neurosurgery Neuromuscular 599 Antiepileptic drugs as prophylaxis for de novo 576 Muscle MRI in a large cohort of patients brain tumour-related epilepsy after craniotomy: with oculopharyngeal muscular dystrophy a systematic review and meta-analysis of harm A Alonso-Jimenez, R H M J M Kroon, and benefits A Alejaldre-Monforte, C Nuñez-Peralta, C Mirian, M Møller Pedersen, A Sabers, C G C Horlings, B G M van Engelen, M Olivé, T Mathiesen L González, E Verges-Gil, C Paradas, C Márquez, M Garibaldi, P Gallano, M J Rodriguez, L Gonzalez-Quereda, C Dominguez Gonzalez, General neurology J Vissing, F Fornander, A-S V Eisum, 608 Complex regional pain syndrome and functional T García-Sobrino, J Pardo, R García-Figueiras, N Muelas, J J Vilchez, S Kapetanovic, G Tasca, neurological disorders – time for reconciliation M Monforte, E Ricci, M T Gomez, J A Bevilacqua, S Popkirov, I Hoeritzauer, L Colvin, A J Carson, J Diaz-Jara, I I Zamorano, R Y Carlier, P Laforet, J Stone A Pelayo-Negro, A Ramos-Fransi, A Martínez, C Marini-Bettolo, V Straub, G Gutiérrez, T Stojkovic, M A Martín, G Morís, PostScript R Fernández-Torrón, A Lopez De Munaín, 615 Letters http://jnnp.bmj.com/ E Cortes-Vicente, L Querol, R Rojas-García, I Illa, J Diaz-Manera 624 Book review on September 30, 2021 by guest. Protected copyright..
Load more

Recommended publications
  • Fibromyalgia and Chronic Fatigue
    Fibromyalgia and Chronic Fatigue Paul G. Swingle, Ph.D., R. Psych. My previous radio program and my present webcast program are both entitled “It’s all in your head!” How I came up with this title was listening to the discouraged patients that I routinely treated, and still treat, who have been told, by the doctors they have consulted, that the pain, discomfort, distress, debilitating fatigue, sleep disturbance and depression that they endure is “all in your head.” What this remark is meant to imply, of course, is that there is no physical cause of the condition and that the symptoms are manifestations of psychological factors. My response to these patients is that “of course it is in your head, where else would it be?” My remark however is not disparaging but rather indicates the actual location of many of the patients symptoms. The brain controls everything so all symptoms are associated with brain activity. The remarkable effectiveness of neurotherapy for the treatment of the symptoms associated with fibromyalgia and chronic fatigue is due to the fact that the brain functioning associated with the symptoms is treated. Although this derogatory sentiment about fibromyalgia patients was widespread among health care providers in the past, it is remarkable to me that it still persists with many doctors to this day. A few days ago I was surfing the internet health news feeds and was dismayed to find an item entitled “Fibromyalgia: A mental illness?” In this item was a quote from a Canadian neurologist stating that fibromyalgia was a term waiting for a definition.
    [Show full text]
  • Vascular Dementia: an Overview of Current Challenges and Gaps
    Stroke and Dementia: what research tells us UK Stroke Assembly 2016 JM Wardlaw University of Edinburgh NHS Lothian www.strokeassembly.org.uk #strokeassembly Definitions Stroke Dementia Sudden onset focal A syndrome where there neurological deficit which is deterioration in last more than 24 hours memory, thinking, attributable to a vascular behaviour such that the defect and has no other person is no longer able identifiable cause to perform everyday activities by themselves www.strokeassembly.org.uk #strokeassembly Stroke – the importance • Stroke, 16.9million new strokes per year, – A third are disabled and dependent – 2nd commonest cause of death – Commonest cause of dependency in adults Infarct, or ischaemic stroke Haemorrhagic stroke www.strokeassembly.org.uk #strokeassembly Cerebrovascular disease – the importance • ‘Silent’ cerebrovascular disease, even bigger issue – Up to 45% of 35.6million dementias – Cognitive impairment, mobility problems Normal White matter disease www.strokeassembly.org.uk #strokeassembly Dementia • 47.5 million people have dementia world wide • 7.7million new cases per year • Affects different people in different ways • Major cause of dependency and disability amongst older people • Alzheimer’s disease commonest cause – 60-70% of cases • Vascular dementia 2nd commonest – 25-45% of all cases www.strokeassembly.org.uk #strokeassembly Dementia: historical perspective 1800’s – Blood vessel diseases 1900’s – Alzheimers disease - dominant 1970’s – ‘Multi-infarct dementia’ – vascular 1990’s–2000’s - ‘Vascular
    [Show full text]
  • TIA Vs CVA (STROKE)
    Phone: 973.334.3443 Email: [email protected] NJPR.com TIA vs CVA (STROKE) What is the difference between a TIA and a stroke? Difference Between TIA and Stroke • Both TIA and stroke are due to poor blood supply to the brain. • Stroke is a medical emergency and it’s a life-threatening condition. • The symptoms of TIA and Stroke may be same but TIA symptoms will recover within 24 hours. TRANSIENT ISCHEMIC ATTACK ● Also known as: TIA, mini stroke 80 E. Ridgewood Avenue, 4th Floor Paramus, NJ 07652 TIA Causes ● A transient ischemic attack has the same origins as that of an ischemic stroke, the most common type of stroke. In an ischemic stroke, a clot blocks the blood supply to part of your brain. In a transient ischemic attack, unlike a stroke, the blockage is brief, and there is no permanent damage. ● The underlying cause of a TIA often is a buildup of cholesterol- containing fatty deposits called plaques (atherosclerosis) in an artery or one of its branches that supplies oxygen and nutrients to your brain. ● Plaques can decrease the blood flow through an artery or lead to the development of a clot. A blood clot moving to an artery that supplies your brain from another part of your body, most commonly from your heart, also may cause a TIA. CEREBROVASCULAR ACCIDENT/STROKE Page 2 When the brain’s blood supply is insufficient, a stroke occurs. Stroke symptoms (for example, slurring of speech or loss of function in an arm or leg) indicate a medical emergency. Without treatment, the brain cells quickly become impaired or die.
    [Show full text]
  • ICD-10 Backs
    Qualifying Dx Codes for Java Backs, Java Decaf Back, & Custom Back ICD-10 Description ICD-10 Description Paraplegia (paraparesis) and quadriplegia B91 Sequelae of poliomyelitis G82.20 - G82.54 (quadriparesis) E75.00 - E75.19 GM2 Gangliosidosis - Other gangliosidosis G83.10 - G83.14 Monoplegia of lower limb Other specified disorders of the brain - E75.23 Krabbe disease G93.89 - G94 Other disorders of the brain in diseases classified elsewhere E75.25 Metachromatic leukodystrophy G95.0 Syringomyelia and syringobulbia Acute infarction of spinal code (embolic) E75.29 Other sphingolipidosis G95.11 (nonembolic) E75.4 Neuronal ceroid lipofuscinosis G95.19 Other vascular myelopathies Myelopathy in diseases classified F84.2 Rett's Syndrome G99.2 elsewhere Monoplegia of lower limb following G04.1 Tropical spastic paraplegia I69.041 - I69.049 nontraumatic subarachnoid hemorrhage Hemiplegia and hemiparesis following G04.89 Other Myelitis I69.051 - I69.059 nontraumatic subarachnoid hemorrhage Monoplegia of lower limb following G10 Huntington's disease I69.141 - I69.149 nontraumatic intracerebral hemorrhage Congenital nonprogressive ataxia - Hemiplegia and hemiparesis following G11.0 - G11.9 I69.151 - I69.159 Hereditary ataxia, unspecified nontraumatic intracerebral hemorrhage Infantile spinal muscular atrophy, type 1 Monoplegia of lower limb following other G12.0 I69.241 - I69.249 (Werdnig-Hoffman) nontraumatic intracranial hemorrhage Hemiplegia and hemiparesis following G12.1 Other inherited spinal muscular atrophy I69.251 - I69.259 other nontraumatic
    [Show full text]
  • Central Pain: Clinical and Physiological J Neurol Neurosurg Psychiatry: First Published As 10.1136/Jnnp.61.1.62 on 1 July 1996
    626Journal ofNeurology, Neurosurgery, and Psychiatry 1996;61:62-69 Central pain: clinical and physiological J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.61.1.62 on 1 July 1996. Downloaded from characteristics David Bowsher Abstract spinothalamic pathway, its relays, or projec- Objectives-To study the clinical and tions may cause central pain,' and modern pathophysiological features of central radiological techniques have tended to con- pain due to damage to the CNS. firm this.9 '" Because of this, and of recent Methods-156 patients (mostly with considerations on pathophysiology,'5 '" the ischaemic strokes, some with infarct after condition is now known as "central poststroke subarachnoid haemorrhage and other pain (CPSP)"'.'7 Stroke is not the only condi- cerebral conditions; one with bulbar and tion causing such central pains of cerebral ori- others with spinal pathology) with central gin.' lxII 2' Furthermore, identical pains occur pain have been investigated clinically and after some spinal lesions.- 22 varying numbers instrumentally with respect to quantitative somatosensory perception thresholds and autonomic Patients function. Between 1983 and 1993, 156 patients have Results-Pain onset was immediate in a been referred to me, in whom a diagnosis of minority; and from a week or two up to central pain due to a cerebral or spinal lesion six years in > 60%. For those with supra- has been made. Of these, 112 (64 (57)%'Y spinal ischaemic lesions, the median age male) had a history of a stroke episode (cere- of onset was 59; dominant and non- brovascular accident, CVA patients), includ- dominant sides were equally affected.
    [Show full text]
  • Genetics of Amyotrophic Lateral Sclerosis
    GENETICS VIGNETTE Genetics of Amyotrophic Lateral Sclerosis J. Gorodenker and L.M. Levy ABBREVIATIONS: ALS ϭ amyotrophic lateral sclerosis; UMN ϭ upper motor neuron; LMN ϭ lower motor neuron; fALS ϭ familial amyotrophic lateral sclerosis; sALS ϭ sporadic amyotrophic lateral sclerosis myotrophic lateral sclerosis (ALS) reflects a heterogeneous The phenotypic heterogeneity of ALS presents several difficul- Agroup of neurodegenerative disorders unified by loss of mo- ties; the diagnosis of ALS is made on clinical grounds and is fun- tor neurons in the primary motor cortex, brain stem, and spinal damentally uncertain, ranging from “suspected” to “possible,” to cord, resulting in progressive muscle weakness. Typical ALS (rep- “probable” to “definite.” There currently is no stated role for neu- resenting 80% of cases) is a limb-predominant disease character- roimaging to support the diagnosis of ALS; however, diagnosis ized by a combination of upper motor neuron (UMN) and lower requires absence of neuroimaging evidence of other disease pro- motor neuron (LMN) symptoms predominantly affecting the ex- cesses that may explain the observed clinical and electrophysio- tremities. ALS may also present in a bulbar form (20%), with early logical signs.4,5 symptoms involving muscles innervated by the lower brain stem, Absence of a sensitive and specific test for ALS often results in affecting articulation, chewing, and swallowing. While the disease significant delay of diagnosis, which ranges from 13–18 months may chronically persist in such form, it usually progresses to the from onset of the disease or longer in patients who present with 1,2 generalized muscle weakness of typical ALS. isolated LMN signs.5 Furthermore, delayed diagnosis restricts the Patients with ALS are more often male and typically present in inclusion of patients in clinical trials and limits early initiation of late middle age.
    [Show full text]
  • Transient Ischemic Attacks (Tias) and Strokes (Cvas)
    CREATED EXCLUSIVELY FOR FINANCIAL PROFESSIONALS Transient Ischemic Attacks (TIAs) and Rx FOR SUCCESS Strokes (CVAs) Obstruction in blood flow (ischemia) to the brain can lead to permanent damage. This is called a cerebrovascular accident (CVA). It is also known as cerebral infarction or stroke. If the symptoms are temporary without permanent brain damage, the event is called a transient ischemic attack (TIA). Rupture of an artery with bleeding into the brain (hemorrhage) is called a CVA, too. Strokes and TIAs are rated based on the underlying cause. The most common cause of TIAs and CVAs is hypertensive and atherosclerotic plaque within the arteries to the brain (aka cerebrovascular disease or CVD). CVD can be complicated by clots (thrombosis) and by emboli from the heart. Because CVD is an indicator of atherosclerosis in other parts of the body, an individual with a history of TIA or CVA is at risk for coronary artery disease and recurrent stroke. Risk factors for CVD include smoking, coronary artery disease, high blood pressure, diabetes, lipid disorders (such as high cholesterol), peripheral arterial disease, and atrial fibrillation. Signs and symptoms of a CVA/TIA include weakness, numbness, headaches, dizziness, nausea, vomiting, paralysis of one side of the body, speech difficulty, and memory defects. Amaurosis fugax, a form of visual TIA, is temporary monocular (one eye) or partial blindness. Tests are done to evaluate the brain circulation, such as a carotid ultrasound (Duplex) or angiogram (MRA). A brain scan (CT and/or MRI) is used to determine if an individual has had a stroke. A TIA will not show on a scan.
    [Show full text]
  • Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives
    International Journal of Molecular Sciences Review Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives Diji Kuriakose and Zhicheng Xiao * Development and Stem Cells Program, Monash Biomedicine Discovery Institute and Department of Anatomy and Developmental Biology, Monash University, Melbourne, VIC 3800, Australia; [email protected] * Correspondence: [email protected] Received: 29 September 2020; Accepted: 13 October 2020; Published: 15 October 2020 Abstract: Stroke is the second leading cause of death and a major contributor to disability worldwide. The prevalence of stroke is highest in developing countries, with ischemic stroke being the most common type. Considerable progress has been made in our understanding of the pathophysiology of stroke and the underlying mechanisms leading to ischemic insult. Stroke therapy primarily focuses on restoring blood flow to the brain and treating stroke-induced neurological damage. Lack of success in recent clinical trials has led to significant refinement of animal models, focus-driven study design and use of new technologies in stroke research. Simultaneously, despite progress in stroke management, post-stroke care exerts a substantial impact on families, the healthcare system and the economy. Improvements in pre-clinical and clinical care are likely to underpin successful stroke treatment, recovery, rehabilitation and prevention. In this review, we focus on the pathophysiology of stroke, major advances in the identification of therapeutic targets and recent trends in stroke research. Keywords: stroke; pathophysiology; treatment; neurological deficit; recovery; rehabilitation 1. Introduction Stroke is a neurological disorder characterized by blockage of blood vessels. Clots form in the brain and interrupt blood flow, clogging arteries and causing blood vessels to break, leading to bleeding.
    [Show full text]
  • Turn Off the Amyotrophic Lateral Sclerosis's Disease Gene
    Meet the Professor Page 1 of 4 Prof. Dongsheng Fan: turn off the amyotrophic lateral sclerosis’s disease gene Submitted Nov 11, 2014. Accepted for publication Nov 12, 2014. doi: 10.3978/j.issn.2305-5839.2014.11.14 View this article at: http://dx.doi.org/10.3978/j.issn.2305-5839.2014.11.14 With more and more celebrities all over the world jumping on the bandwagon of the Ice Bucket Challenge, amyotrophic lateral sclerosis (ALS) has been put in the spotlight. Though this event in a way had risen the awareness of ALS, there are still so many unsolved problems about it, such as the difficulty of accurate diagnosis and complete treatment. To discuss the hotspots and recent advances in this area, Annals of Translational Medicine has the pleasure to invite Prof. Dongsheng Fan (Figure 1), one of the leading experts on degenerative diseases of the nervous system in China, to unveil the “mystery” of ALS and find out what’s newest about this disease. Prof. Fan will also work on a special issue about ALS as the guest editor of Annals of Translational Medicine subsequently. Figure 1 Professor Dongsheng Fan. Introduction Professor Dongsheng Fan is currently the Chief of Neurology in the Peking University Third Hospital, From a professional perspective, what are the disease a member of the standing committee of the Chinese characteristics of ALS? Neurological Society, the vice-chairman of the Beijing Prof. Fan: Clinically, ALS, AD, PD, and multiple system Branch of the Chinese Academy of Neurology, a member atrophy (MSA) are all typical degenerative diseases of the of the Board of Directors of the World Stroke Organization nervous system.
    [Show full text]
  • Guidelines for Diagnosis and Treatment of Moyamoya Disease (Spontaneous Occlusion of the Circle of Willis)
    Neurol Med Chir (Tokyo) 52, 245¿266, 2012 Guidelines for Diagnosis and Treatment of Moyamoya Disease (Spontaneous Occlusion of the Circle of Willis) Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis; Health Labour Sciences Research Grant for Research on Measures for Intractable Diseases CHAPTER I: CONCEPTS OF THE DISEASE Concepts of the Disease (ii) Abnormal vascular networks in the vicinity of the occlusive or stenotic lesions in the ar- The characteristics of moyamoya disease (spontane- terial phase. ous occlusion of the circle of Willis, cerebrovascular (iii) Bilaterality of findings (i) and (ii). ``moyamoya'' disease) on cerebral angiography were (2) However, when magnetic resonance imaging reported for the first time in 1957,8) and the concept (MRI) and magnetic resonance angiographic of moyamoya disease as a separate disease entity (MRA) findings meet all of the following criteria, was established in the 1960s.1–3,6,7) Pathologically, cerebral angiography can be omitted. See the moyamoya disease is characterized by chronic ``Guidelines for Diagnostic Imaging by MRI and progressive stenosis of the terminal portion of the MRA.'' bilateral internal carotid arteries, which leads to the (i) MRA shows stenosis or occlusion of the ter- formation of an abnormal vascular network com- minal portion of the intracranial internal posed of collateral pathways at the base of the brain carotid artery or proximal portions of the (moyamoya vessels at the base of the brain) anterior and/or the middle cerebral artery. (`moyamoya' is the Japanese term for a ``puff of (ii) MRA shows abnormal vascular networks in smoke,'' which has been used to describe the appear- the basal ganglia.
    [Show full text]
  • CNS Findings in Chronic Fatigue Syndrome and a Neuropathological Case Report Kimberly Ferrero, Mitchell Silver, Alan Cocchetto, Eliezer Masliah and Dianne Langford
    Downloaded from http://jim.bmj.com/ on April 7, 2017 - Published by group.bmj.com Original research CNS findings in chronic fatigue syndrome and a neuropathological case report Kimberly Ferrero,1 Mitchell Silver,1 Alan Cocchetto,2 Eliezer Masliah,3 Dianne Langford1 1Lewis Katz School of ABSTRACT Medicine at Temple Chronic fatigue syndrome (CFS) is characterized as a Significance of this study University, Philadelphia, Pennsylvania, USA persistent, debilitating complex disorder of unknown 2State University of etiology, whereby patients suffer from extreme New York at Alfred, fatigue, which often presents with symptoms that What is already known about this Engineering Technologies, include chronic pain, depression, weakness, mood subject? Alfred, New York, USA disturbances, and neuropsychological impairment. In ▸ 3University of California San Chronic fatigue syndrome (CFS) is 6 months Diego, La Jolla, California, this mini review and case report, we address central or more of persistent cognitive and physical USA nervous system (CNS) involvement of CFS and fatigue, with brain-related symptoms present neuropathological autopsy findings from a varying among patients Correspondence to patient who died with a prior diagnosis of CFS. ▸ CFS is classified as a neurological disorder Dianne Langford, Lewis Katz School of Medicine at Among the most remarkable pathological features of and increasing evidence supports CFS as a Temple University, the case are focal areas of white matter loss, neurite disease of the nervous and immune 3500 North Broad Street, beading, and neuritic pathology of axons in the systems MERB 750, Philadelphia, white matter with axonal spheroids. Atypical ▸ In the central nervous system (CNS), CFS PA 19140, USA; neurons displaying aberrant sprouting processes in [email protected] may be triggered by exposure to response to injury are observed throughout cortical radionuclides, viral or microbial infection, Accepted 14 March 2017 gray and white matter.
    [Show full text]
  • Contents Editorial Commentaries Multiple Sclerosis
    March 2019 Volume 90 Issue 3 90 Impact 3 Factor 7.144 Volume 90 Issue 3 Volume Contents Volume 90 Issue 3 | JNNP March 2019 Pages 247–368 Pages JOURNAL OF NEUROLOGY NEUROSURGERY & PSYCHIATRY NEUROSURGERY OF NEUROLOGY JOURNAL Editorial commentaries Neuromuscular J Neurol Neurosurg Psychiatry: first published as on 1 March 2019. Downloaded from ISSUE HIGHLIGHTS 247 The unintended consequences of NICE 294 Neurochemical correlates of functional decline Epilepsy – Surgery at it’s best Amyotrophic Lateral Sclerosis – Age of onset G Giovannoni Multiple Sclerosis – 10 years of risk sharing in amyotrophic lateral sclerosis Stroke – Endovascular therapy outcomes Neuropathy – Mining the genes PTSD – Therapy for Veterans I Cheong, D K Deelchand, L E Eberly, M Marja ska, G Manousakis, G Guliani, D Walk, March 2019 March 249 Epilepsy surgery at its best: randomised ń jnnp.bmj.com prospective controlled trials in neurosurgery G Öz Cover image: Brain tree. are no magic Editor P C Warnke Cognitive neurology Matthew C Kiernan (Australia) 302 Brain mechanisms underlying apathy Deputy Editors C Le Heron, C B Holroyd, J Salamone, M Husain Karen L Furie (USA) 250 What does age at onset in ALS tell us about Satoshi Kuwabara (Japan) the genetic basis of the disease? Lawrence Wong (China) J H Veldink Associate Editors Cerebrovascular disease Alan Carson (UK) 313 Impact of infarct location on functional Nick Ward (UK) Multiple sclerosis outcome following endovascular therapy for Peter Warnke (USA) 251 Assessing the long-term effectiveness of Commissioning Editor
    [Show full text]